Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients

NCT03357653 is registered in ClinicalTrials.gov with Ewha Womans University as lead sponsor.

NCT NCT03357653
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03357653 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients
Lead sponsor
Ewha Womans University
Phase
Phase 3
Overall status
Unknown status
Start date
January 30, 2018
Completion date
December 31, 2021
Enrollment
174 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glomerulonephritis, immunoglobulin a (iga)